Giuseppe Lombardi, MD, PhD, Veneto Institute of Oncology, Padua, Italy, discusses the current endeavors to advance treatments for glioblastoma, discussing the combination of immunotherapies with other targeted agents, the application of immunotherapies in novel ways, and the use of Carthera to disrupt the blood-brain barrier (BBB). Dr Lombardi also considers the concept of fortifying the current standard of care regimens with other agents to enhance tumor DNA damage. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.